Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07167329 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Real-World Effectiveness and Pharmacogenetics of Belzutifan in VHL Syndrome: The BELIEVE-VHL Trial

Study acronym: BELIEVE-VHL
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated September 11, 2025 (before its estimated February 1, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
The BELIEVE-VHL Trial is a prospective real-life study designed to evaluate the therapeutic effects, benefits, and adverse effects of belzutifan, as well as the timing of treatment response and disease progression in patients with von Hippel-Lindau (VHL) syndrome.
Trial Details
NCT Number NCT07167329
Lead Sponsor José Claudio Casali da Rocha
Collaborators: AC Camargo Cancer Center
Conditions
(from sponsor)		 Von Hippel Lindau, Von Hippel Lindau Disease, Von Hippel Lindau-Deficient Clear Cell Renal Cell Carcinoma, Hemangioblastoma (HB) of the Central Nervous System (CNS), PNET, Retinal Angiomatous Proliferation, Pheochromocytoma/Paraganglioma, Endolymphatic Sac Tumor
Related terms Carcinoma, Renal Cell, Hemangioblastoma, Neuroectodermal Tumors, Primitive, Paraganglioma, Pheochromocytoma, von Hippel-Lindau Disease
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov